Nexara Health — Health Canada Drug Establishment Licence #3-002896

Comparator supply for NCT07468071

Rollover Study for Participants Who Have Been Treated With and Are Continuing to Benefit From Opnurasib as a Single Agent or in Combination With Other Study Treatments

Sponsor: Novartis Pharmaceuticals (INDUSTRY). Phase: PHASE1, PHASE2. Status: Recruiting. Countries: Belgium, Canada, China, Denmark, France, Italy, Japan, Malaysia, South Korea, Spain. Last update posted 2026-09-04.

Registry record: https://clinicaltrials.gov/study/NCT07468071.

Canadian-labelled trametinib

3 marketed Canadian product(s) from 1 manufacturer(s) contain trametinib. Available strengths: 0.5 MG, 2 MG, 4.7 MG. Because the comparator is registered in Canada, supply can be arranged without a Special Access request and with the Canadian label, package insert and lot documentation the protocol expects.

What we supply

Frequently asked questions

Can Nexara supply Canadian-labelled trametinib as a trial comparator?

Yes. We source Canadian-marketed trametinib under Health Canada Drug Establishment Licence #3-002896 and ship it with Certificate of Analysis, batch number and expiry documentation for use as a comparator or rescue supply in NCT07468071.

What documentation comes with each shipment?

Certificate of Analysis, manufacturer batch and expiry records, chain-of-custody documentation from the Canadian supply chain, and temperature records where cold chain applies. Blinding-ready packaging is available on request.

How long does comparator supply take?

Quotes are returned within one business day. Lead time depends on the presentation and the destination country's import route — typically 10 to 21 days once the importer's licence and any notification are in place.

Request comparator quote

Request comparator quote or call +1-431-588-9055.

Related pages